Parties/Counsel Are Strongly Encouraged to Appear Telephonically
The Number of Persons Permitted In the Courtroom is Extremely Limited
Facial Masks/Coverings Are Mandatory for Courthouse/Courtroom Entry
MOVING PARTY: Defendant Sang Bong Lee
OPPOSITION: Plaintiff, Cross-Defendant, and Cross-Complainant Komipharm International Co., Ltd
Plaintiff Komipharm International Co., Ltd., (“Komipharm”) sues Defendant/Cross-Defendant Sang Bong Lee (“Lee”) based on allegations that Lee is not entitled to patent rights or profits from an arsenic-based anticancer drug.
In October 2004, U.S. Patent Application No. 10/962,357 (“the 357 application”) was filed listing Lee and Yong Jin Yang (“Yang”), President of Komipharm, as the inventors of the drug. In 2008, Lee signed an agreement by which he assigned his rights to the drug to Komipharm. Komipharm alleges that it subsequently discovered that Lee was not the inventor of the drug. Komipharm moved to remove Lee and Yang as inventors and moved to
Hearing Date
June 29, 2020
Type
Other Commercial/Business Tort (General Jurisdiction)
For full print and download access, please subscribe at https://www.trellis.law/.
Parties/Counsel Are Strongly Encouraged to Appear Telephonically
The Number of Persons Permitted In the Courtroom is Extremely Limited
Facial Masks/Coverings Are Mandatory for Courthouse/Courtroom Entry
MOVING PARTY: Defendant Sang Bong Lee
OPPOSITION: Plaintiff, Cross-Defendant, and Cross-Complainant Komipharm International Co., Ltd
Plaintiff Komipharm International Co., Ltd., (“Komipharm”) sues Defendant/Cross-Defendant Sang Bong Lee (“Lee”) based on allegations that Lee is not entitled to patent rights or profits from an arsenic-based anticancer drug.
In October 2004, U.S. Patent Application No. 10/962,357 (“the 357 application”) was filed listing Lee and Yong Jin Yang (“Yang”), President of Komipharm, as the inventors of the drug. In 2008, Lee signed an agreement by which he assigned his rights to the drug to Komipharm. Komipharm alleges that it subsequently discovered that Lee was not the inventor of the drug. Komipharm moved to remove Lee and Yang as inventors and moved to